Results for tag: "Idiopathic Pulmonary Fibrosis"

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease that affects the interstitium, the tissue between the air sacs of the lungs. It is a form of interstitial lung disease, and is characterized by scarring of the lungs, leading to difficulty breathing. IPF is a rare disease, and is most commonly seen in people over the age of 50. It is a major cause of morbidity and mortality in cardiology, and is associated with a poor prognosis. IPF is a complex disease, and there is no known cure. Treatment options are limited, and focus on slowing the progression of the disease and managing symptoms. These treatments include medications, oxygen therapy, and lung transplantation. The IPF market is a rapidly growing market, with a number of companies developing treatments and therapies for the disease. These companies include Boehringer Ingelheim, Gilead Sciences, Galapagos, FibroGen, and InterMune. Show Less Read more